How should I taper a patient off 20 mg of Lexapro (escitalopram)?

Tapering Lexapro 20 mg: A Gradual, Hyperbolic Approach

Taper Lexapro 20 mg gradually over several months using progressively smaller dose reductions (hyperbolic taper), reducing by approximately 10% of the current dose every 2-4 weeks, continuing down to very low doses (1-2 mg or less) before complete discontinuation to minimize withdrawal symptoms.

Core Tapering Strategy

The FDA label explicitly states that "a gradual reduction in the dose rather than abrupt cessation is recommended whenever possible" and that if intolerable symptoms occur, you should resume the previous dose and decrease more gradually 1. However, the label provides minimal specific guidance on the actual tapering schedule.

Why Hyperbolic (Not Linear) Tapering

The relationship between SSRI dose and serotonin transporter occupancy follows a hyperbolic curve—meaning small dose reductions at lower doses cause disproportionately large changes in receptor effects 2. Linear tapers (e.g., reducing by 5 mg every 2 weeks) create increasingly severe biological disruption as you approach lower doses, which explains why many patients fail traditional short tapers.

Practical Tapering Protocol

For Standard Risk Patients (Short Duration, Lower Doses, No Prior Withdrawal)

• Week 0-2: 20 mg → 18 mg (10% reduction)
• Week 2-4: 18 mg → 16 mg
• Week 4-6: 16 mg → 14 mg
• Week 6-8: 14 mg → 12 mg
• Continue reducing by ~10% of current dose every 2 weeks
• Final stages: 5 mg → 3 mg → 2 mg → 1 mg → 0.5 mg → stop
• Total duration: 3-6 months

For Higher Risk Patients (Long Duration >1 Year, Higher Doses, Prior Withdrawal Symptoms)

Higher doses and longer treatment duration significantly increase withdrawal risk 3. These patients require:

• Slower reductions: 5-10% of current dose every 2-4 weeks
• Smaller final doses: Taper to 1 mg or less before stopping
• Longer duration: 6-12 months or longer 4, 5
• Liquid formulation or compounding: May be necessary to achieve very small doses (e.g., 1-2 mg increments) 5

Critical Implementation Details

Monitoring Schedule

• Follow-up every 2-4 weeks during active tapering 4
• Monitor specifically for withdrawal symptoms: dizziness, muscle tension, chills, confusion, crying, "brain zaps," insomnia, anxiety 3
• Distinguish withdrawal from relapse (withdrawal typically peaks within 1-2 weeks and improves; relapse develops more gradually)

When to Pause or Slow the Taper

If withdrawal symptoms emerge:

1. Pause the taper at current dose for 2-4 weeks until symptoms resolve
2. If symptoms persist or worsen, increase back to previous dose 1
3. Once stabilized, resume tapering at a slower rate (e.g., 5% reductions instead of 10%)

Avoid Common Pitfalls

Never use alternate-day dosing (e.g., 20 mg every other day to "average" 10 mg daily). This creates dramatic fluctuations in receptor occupancy and significantly increases withdrawal risk 6. Escitalopram's 27-32 hour half-life means every-other-day dosing causes severe oscillations in serotonin transporter inhibition.

Do not stop at 5 mg or 10 mg thinking these are "low enough." The hyperbolic dose-response curve means going from 5 mg to 0 mg causes a larger biological change than going from 20 mg to 15 mg 2, 7.

Special Considerations

Patient Education

Inform patients that:

• Withdrawal symptoms are common (occurring in >50% of patients) but manageable with slow tapering 4
• Symptoms do not indicate addiction or weakness
• The process may take months, which is normal and appropriate
• They should report any new symptoms immediately rather than "toughing it out"

Risk Factors for Difficult Withdrawal

Higher risk patients include those with:

• Treatment duration >1 year
• Current dose at maximum (20 mg) 3
• Previous failed taper attempts
• History of anxiety or panic disorder
• Concurrent benzodiazepine use (note: if both medications need tapering, taper opioids/SSRIs first due to lower withdrawal risks compared to benzodiazepines 8, 9)

Formulation Options

• Tablets: 20 mg, 10 mg, 5 mg (scored) 1
• For doses <5 mg: Consider liquid formulation (5 mg/5 mL, though currently not marketed 1) or compounded preparations
• Alternative: Some patients dissolve tablets in water for more precise dosing, though this is off-label

When Tapering May Not Be Appropriate

Carefully weigh risks versus benefits before initiating taper. Consider continuing treatment if:

• Recent severe depressive episode (<6-9 months remission)
• Multiple prior relapses requiring treatment
• Significant life stressors present
• Patient preference after informed discussion of risks/benefits

The goal is minimizing morbidity and maintaining quality of life—sometimes this means continuing medication rather than forcing discontinuation 10.